CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
Panelists discuss that when selecting a chimeric antigen receptor T-cell (CAR T) product for a patient with an aggressive clinical course and eligibility for cellular therapy, key considerations include urgency, toxicity risks, and efficacy. Factors such as time to manufacture, cytokine release syndrome/immune effector cell–associated neurotoxicity syndrome rates, long-term remission data, and antigen specificity guide decision-making.
EP: 1.DLBCL in Focus: Transforming Outcomes With CAR T Therapy
EP: 2.Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
EP: 3.Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
EP: 4.TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
EP: 5.CAR T in the Real World: Clinician Perspectives on Outcomes, Toxicity, and Patient Management
EP: 6.Rethinking CAR T Timing: Insights on CAR T Efficacy and Patient Selection
EP: 7.Personalizing CAR T: Making the Right Call for Each Patient
EP: 8.Auto-SCT or CAR T? A Case-Based Discussion in Relapsed DLBCL
EP: 9.Transplant-Eligible, CAR T Considered: How Do We Decide?
EP: 10.CAR T in High-Risk DLBCL: Making the Right Choice in Aggressive Disease
EP: 11.The Future of DLBCL: Innovations in Therapy and Patient Care
Video content above is prompted by the following:
- Given the aggressive clinical course and patient eligibility for cellular therapy and considering the urgency, toxicity risks, and efficacy profiles, what factors would guide your choice between available CAR T products?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
